Order Article Reprints

Liu D, Wu J, Lin C, Ding S, Lu S, Fang Y, Huang J, Hong J, Gao W, Zhu S, et al. The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial. Cancers. 2022; 14(13):3221. https://doi.org/10.3390/cancers14133221

Liu, Deyue, Jiayi Wu, Caijin Lin, Shuning Ding, Shuangshuang Lu, Yan Fang, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, and et al. 2022. "The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial" Cancers 14, no. 13: 3221. https://doi.org/10.3390/cancers14133221

Liu, D., Wu, J., Lin, C., Ding, S., Lu, S., Fang, Y., Huang, J., Hong, J., Gao, W., Zhu, S., Chen, X., Huang, O., He, J., Chen, W., Li, Y., Shen, K., & Zhu, L. (2022). The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial. Cancers, 14(13), 3221. https://doi.org/10.3390/cancers14133221